Intravenous Lidocaine Plus Intratracheal Dexmedetomidine on Postoperative Sore Throat

NANot yet recruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

April 25, 2025

Primary Completion Date

September 15, 2025

Study Completion Date

September 25, 2025

Conditions
DexmedetomidineLidocaineSore Throat
Interventions
DRUG

Intracheal dexmedetomidine

Group D received equal volume normal saline was injected intravenously 3 min before tracheal intubation and tracheal spray with dexmedetomidine (1 μg/kg) mixed with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia

DRUG

Intravenous lidocaine

Group L received lidocaine 1.5 mg/kg was injected intravenously 3 min before endotracheal intubation and tracheal spray with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia

DRUG

Intravenous lidocaine combined with intracheal dexmedetomidine

Group LD received lidocaine 1.5 mg/kg was injected intravenously 3 min before endotracheal intubation and tracheal spray with dexmedetomidine (1 μg/kg) mixed with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia

DRUG

Saline (NaCl 0,9 %) (placebo)

Group C received equal volume normal saline was injected intravenously 3 min before tracheal intubation and tracheal spray with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia

All Listed Sponsors
lead

Anqing Municipal Hospital

OTHER

NCT06952309 - Intravenous Lidocaine Plus Intratracheal Dexmedetomidine on Postoperative Sore Throat | Biotech Hunter | Biotech Hunter